Diclofenac

SAM 2.0 Treatment Provides Non-Surgical Pain Relief for Federal Employees and Veterans Suffering From Knee Arthritis

Retrieved on: 
Wednesday, January 27, 2021
Medical specialties, Skeletal disorders, Musculoskeletal system, Clinical medicine, Rheumatology, Hepatotoxins, Nonsteroidal anti-inflammatory drugs, Aging-associated diseases, Osteoarthritis, Diclofenac, Arthritis, Therapeutic ultrasound

A recent research study published in The Open Orthopaedics Journal highlights the efficacy of SAM ultrasound when combined with a 1% diclofenac ultrasound gel patch in the treatment of pain and complications due to knee osteoarthritis.

Key Points: 
  • A recent research study published in The Open Orthopaedics Journal highlights the efficacy of SAM ultrasound when combined with a 1% diclofenac ultrasound gel patch in the treatment of pain and complications due to knee osteoarthritis.
  • The study concludes that "Sustained Acoustic Medicine combined with 1% topical diclofenac rapidly reduced pain and improved function in patients with moderate to severe osteoarthritis-related knee pain.
  • The clinical findings suggest that this treatment approach may be used as a conservative, non-invasive treatment option for patients with knee osteoarthritis."
  • ZetrOZ Systems produced UltrOZ, samSport and samPro 2.0 to provide safe and effective treatment options for prevalent conditions such as arthritis.

IBSA Reacquires Commercial Rights to the Flector® Brand in the US

Retrieved on: 
Tuesday, January 12, 2021
Clinical pharmacology, Chloroarenes, Diclofenac, Hepatotoxins, Medical prescription, Sprain, Health

With the return of the commercial rights of Flector, a product that IBSA has developed, IBSA now offers two prescription topical drugs to treat acute pain due to minor strains, sprains, and contusions.

Key Points: 
  • With the return of the commercial rights of Flector, a product that IBSA has developed, IBSA now offers two prescription topical drugs to treat acute pain due to minor strains, sprains, and contusions.
  • As of January 2021, marketing rights for Flector have reverted to IBSA, the originator of the product.
  • A promotional program is available to support Flector prescribers and patients with product samples, literature, and improved patient savings programs.
  • Information about Flector and Flector savings programs can be found at www.Flector.com.

Advisory - Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) beyond 20 weeks of pregnancy and risk of kidney damage in unborn babies, leading to low amniotic fluid

Retrieved on: 
Friday, October 30, 2020
Hepatotoxins, Nonsteroidal anti-inflammatory drugs, Medical specialties, Obstetrics, Health, Pregnancy, Reproductive health, Diclofenac, Drugs in pregnancy

What to do: While Health Canada is investigating this issue, the Department is advising pregnant women not to use NSAIDs at 20 weeks or later in pregnancy unless advised to do so by their healthcare professional.

Key Points: 
  • What to do: While Health Canada is investigating this issue, the Department is advising pregnant women not to use NSAIDs at 20 weeks or later in pregnancy unless advised to do so by their healthcare professional.
  • NSAIDs are commonly used to relieve pain and reduce fevers.
  • Donot use NSAIDs at 20 weeks or later in pregnancy unless advised to do so by your healthcare professional.
  • Report any health product side effects or complaints to Health Canada.

Dr. Reddy’s Q2 & H1 FY21 Financial Results

Retrieved on: 
Wednesday, October 28, 2020
Biotechnology, Pharmaceutical, Health, Chloroarenes, Diclofenac, Hepatotoxins, Otic, Chemical compounds

We promptly engaged leading outside cybersecurity experts, launched a comprehensive containment and remediation effort and investigation to address the incident.

Key Points: 
  • We promptly engaged leading outside cybersecurity experts, launched a comprehensive containment and remediation effort and investigation to address the incident.
  • We further strengthened our development pipeline for COVID-19 treatment drugs including the vaccine candidate Sputnik V.
    Revenues from GG segment at Rs.
  • We launched nine new products including Ciprofloxacin & Dexamethasone Otic Suspension, Fulvestrant Injection, OTC Diclofenac and OTC Olapatadine.
  • As % to revenues these are: Q2 FY21: 8.9% | Q1 FY 21: 9.0% | Q2 FY20: 7.6%.

Amneal & PL Developments Launch Store Brand Program of Over-the-Counter (“OTC”) Diclofenac Sodium Topical Gel, 1%

Retrieved on: 
Thursday, October 8, 2020
Biotechnology, FDA, Pharmaceutical, Health, Pharmaceutical companies, RTT, Nonsteroidal anti-inflammatory drugs, Asset, Chloroarenes, Diclofenac, Hepatotoxins, Balance sheet, Amneal Pharmaceuticals, Brand, Amneal, PLD

Prior to switching OTC, sales of diclofenac sodium topical gel, 1% totaled approximately $250 million.

Key Points: 
  • Prior to switching OTC, sales of diclofenac sodium topical gel, 1% totaled approximately $250 million.
  • We, along with our partners at PLD, are excited to announce the launch of the first brand matching portfolio of store brand Voltaren OTC, said Chirag and Chintu Patel, Co-Chief Executive Officers.
  • Mitch Singer, CEO of PL Developments, said, We are thrilled to expand our product partnership with Amneal.
  • By working together, we are able to bring the first truly brand matching portfolio of store brand Voltaren OTC to US retailers.

Dr. Reddy's Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market

Retrieved on: 
Wednesday, September 9, 2020
Health, Pharmaceutical, Health care, Health, Nonsteroidal anti-inflammatory drugs, Hepatotoxins, Pharmaceutical companies, Acetic acids, Chloroarenes, RTT, Diclofenac, Dr. Reddy's Laboratories, Over-the-counter drug, Hair gel

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of over-the-counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren Arthritis Pain in the U.S. market.

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of over-the-counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren Arthritis Pain in the U.S. market.
  • We are pleased to partner with Encube Ethicals to bring this product to market for the benefit of consumers.
  • Dr. Reddys Diclofenac Sodium Topical Gel, 1% (OTC), is used for the temporary relief of arthritis pain ONLY in the following areas:
    Voltaren Arthritis Pain brand had total U.S. retail sales of approximately $44 million since launch in May 2020 according to IRI*.
  • Dr. Reddys Diclofenac Sodium Topical Gel, 1% (OTC), will soon be available in multiple pack sizes to allow consumers a variety of purchasing options.

Perrigo Announces The Store Brand Equivalent Of Voltaren® Arthritis Pain Is Available At U.S. Major Retailers Nationwide

Retrieved on: 
Tuesday, September 8, 2020
Pharmaceutical companies, Nonsteroidal anti-inflammatory drugs, RTT, Acetic acids, Chloroarenes, Hepatotoxins, Companies, Perrigo, Health care, Diclofenac, Brand, Salonpas

This product is packaged and marketed under retailers 'own-brand' labels across all channels and formats, providing consumers with access to the only store brand diclofenac sodium topical gel, 1% for arthritis pain without a prescription.

Key Points: 
  • This product is packaged and marketed under retailers 'own-brand' labels across all channels and formats, providing consumers with access to the only store brand diclofenac sodium topical gel, 1% for arthritis pain without a prescription.
  • Generic prescription annual sales of Voltaren Arthritis Pain before it switched to OTC were approximately $250 million.
  • Perrigo Executive Vice President and President Consumer Self-Care Americas Rich Sorotacommented, "This first-to-market store brand launch is a testament to the power, speed and versatility of our OTC self-care platform and our R&D capabilities.
  • Successfully bringing Rx-to-OTC switches to market enhances our retail partners 'own-brand' offerings and continues to differentiate Perrigo in the marketplace."

Walgreens Introduces Owned Brand Arthritis Pain Relief Gel Alongside Personalized Pain Management Support

Retrieved on: 
Tuesday, September 1, 2020
Medical Supplies, Retail, Health, Convenience store, General Health, Pharmaceutical, Pain, Health, Perception, RTT, Acute pain, Hepatotoxins, Nonsteroidal anti-inflammatory drugs, Diclofenac, Walgreens, Arthritis, Pain management, Pharmacy, Walgreens Pain Solutions and Therapies, Global Healthy Living Foundation

Walgreens today announced new offerings to support people with chronic and acute pain, including the launch of Walgreens brand diclofenac gel, an over-the-counter original prescription-strength arthritis pain relief in topical form.

Key Points: 
  • Walgreens today announced new offerings to support people with chronic and acute pain, including the launch of Walgreens brand diclofenac gel, an over-the-counter original prescription-strength arthritis pain relief in topical form.
  • In addition, patients can receive free one-on-one consultations with Walgreens pharmacists who received specialized training in providing empathetic care and personalized pain management solutions.
  • Walgreens pharmacists are specially trained to empathetically engage with patients and offer them comprehensive, personalized options.
  • Walgreens pain relief options include diclofenac gel, which can be used to treat pain at its source hand, wrist, elbow, foot, ankle or knee and is available at Walgreens and Walgreens.com .

GSK Consumer Healthcare teams up with Paula Abdul for the launch of Voltaren Arthritis Pain Gel

Retrieved on: 
Thursday, June 11, 2020
Medical specialties, RTT, Medicine, Rheumatology, Health, Chloroarenes, Diclofenac, Arthralgia, Arthritis

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8731451-gsk-partners-with-paula-...

Key Points: 
  • Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8731451-gsk-partners-with-paula-...
    To launch the OTC offering, Voltaren is teaming up with music superstar Paula Abdul, who uses Voltaren for her arthritis pain.
  • Staying active is important for arthritis patients everywhere, and together, Voltaren and Paula Abdul will inspire people to "rediscover the joy of movement".
  • "I'm excited to partner with Voltaren Arthritis Pain Gel to share my personal journey with arthritis and success using Voltaren," Paula said.
  • The active ingredient in Voltaren Arthritis Pain Gel, diclofenac sodium, is an effective medicine that is clinically proven to relieve joint pain due to arthritis.

Voltaren Arthritis Pain and the Arthritis Foundation Announce Multi-Year Partnership to Help People Living with Osteoarthritis

Retrieved on: 
Monday, April 13, 2020
Medical specialties, Medicine, Rheumatology, RTT, Health, Skeletal disorders, Aging-associated diseases, Diclofenac, Arthritis Foundation, Arthritis, Arthralgia

We're excited to take the first step in that journey by donating 100 percent of our pre-order profits from Voltaren Arthritis Pain to support the Arthritis Foundation's work."

Key Points: 
  • We're excited to take the first step in that journey by donating 100 percent of our pre-order profits from Voltaren Arthritis Pain to support the Arthritis Foundation's work."
  • The multi-year partnership kicks off today, with GSK's Voltaren Arthritis Pain pre-order period spanning until May 12 as part of the Arthritis Foundation's Promotions that Give Back .
  • The active ingredient in Voltaren Arthritis Pain, diclofenac sodium, is an effective medicine that is clinically proven to relieve joint pain due to arthritis.
  • Voltaren Arthritis Pain penetrates throughthe skin at the application site to deliver arthritis pain relief.